A study of Roche's Gazyva has raised the prospect of a first approved therapy for primary membranous nephropathy (pMN), a rare autoimmune kidney disorder. The phase 3 MAJESTY trial of anti-CD20 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results